Adavosertib (MK-1775)

Name: Adavosertib (MK-1775)
Brand: Selleck Chemicals
SKU: S1525
Rating: 5 (138 reviews)

For research use only.

Catalog No.S1525 Synonyms: AZD1775

138 publications

Adavosertib (MK-1775) Chemical Structure

CAS No. 955365-80-7

Adavosertib (MK-1775, AZD1775) is a potent and selective Wee1 inhibitor with IC50 of 5.2 nM in a cell-free assay; hinders G2 DNA damage checkpoint. Phase 2.

Selleck's Adavosertib (MK-1775) has been cited by 138 publications

Cancer Cell, 2020, 15 pii: S1535-6108(20)30164-1

PubMed: 32359397 ( click the link to review the publication )

Nat Med, 2019, 25(5):838-849

PubMed: 31011202 ( click the link to review the publication )

Cancer Cell, 2019, 35(3):519-533

PubMed: 30889383 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cell, 2018, 173(1):104-116

PubMed: 29502971 ( click the link to review the publication )

Cell, 2013, 155(5):1088-103

PubMed: 24267891 ( click the link to review the publication )

Sci Adv, 2021, 7(7)eabd2645

PubMed: 33579708 ( click the link to review the publication )

Cell Rep, 2021, 34(11):108870

PubMed: 33730585 ( click the link to review the publication )

Cell Rep, 2021, 34(9):108808

PubMed: 33657372 ( click the link to review the publication )

FEBS J, 2021, 10.1111/febs.15747

PubMed: 33529438 ( click the link to review the publication )

Biochem Pharmacol, 2021, 188:114494

PubMed: 33684390 ( click the link to review the publication )

Cell Death Differ, 2021, 10.1038/s41418-020-00733-4

PubMed: 33531658 ( click the link to review the publication )

Life Sci Alliance, 2021, 4(3)e202000980

PubMed: 33402344 ( click the link to review the publication )

Sci Adv, 2020, 6(24):eaaz7808

PubMed: 32577513 ( click the link to review the publication )

Clin Cancer Res, 2020, 27 pii: clincanres

PubMed: 32341033 ( click the link to review the publication )

Cell Rep, 2020, 33(9):108449

PubMed: 33264622 ( click the link to review the publication )

Haematologica, 2020, 12;haematol.2019.233445

PubMed: 32165486 ( click the link to review the publication )

Cancer Lett, 2020, 472:119-131

PubMed: 31866466 ( click the link to review the publication )

Ther Adv Med Oncol, 2020, 12:1758835920974201

PubMed: 33425022 ( click the link to review the publication )

Mol Oncol, 2020, 10.1002/1878-0261.12882

PubMed: 33320980 ( click the link to review the publication )

Br J Haematol, 2020, 21

PubMed: 32314355 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(1):148-163

PubMed: 32064158 ( click the link to review the publication )

Am J Cancer Res, 2020, 1;10(3):908-924

PubMed: 32266099 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0507

PubMed: 32229503 ( click the link to review the publication )
J Cell Mol Med, 2020, 27

PubMed: 32459381 ( click the link to review the publication )

Int J Mol Sci, 2020, 18;21(8):2825

PubMed: 32325639 ( click the link to review the publication )

Cancer Cell Int, 2020, 20:253

PubMed: 32565737 ( click the link to review the publication )

Ther Adv Hematol, 2020, 11:2040620719898373

PubMed: 32010435 ( click the link to review the publication )

Diagnostics (Basel), 2020, 10(2)

PubMed: 32098452 ( click the link to review the publication )

Cell Rep, 2020, 32(2):107901

PubMed: 32668239 ( click the link to review the publication )

JCI Insight, 2020, 143474

PubMed: 33320833 ( click the link to review the publication )

J Neurooncol, 2020, 10.1007

PubMed: 32180106 ( click the link to review the publication )

Cancers (Basel), 2020, 12(6):1503

PubMed: 32526907 ( click the link to review the publication )

FEBS J, 2020, 10.1111/febs.15280

PubMed: 32144855 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2189

PubMed: 31097698 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-0775

PubMed: 31806643 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(11):3430-3442

PubMed: 30755439 ( click the link to review the publication )

Leukemia, 2019, 10.1038/s41375-019-0456-2

PubMed: 30967619 ( click the link to review the publication )

Haematologica, 2019, 104(11):2225-2240

PubMed: 30819918 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(7):2290-2304

PubMed: 30538111 ( click the link to review the publication )

J Cell Biol, 2019, 218(5):1531-1552

PubMed: 30858191 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472.CAN-18-3374

PubMed: 31551363 ( click the link to review the publication )

Elife, 2019, e46902

PubMed: 31264963 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):463

PubMed: 31718704 ( click the link to review the publication )

Cancers (Basel), 2019, 11(11)

PubMed: 31703356 ( click the link to review the publication )

Cancers (Basel), 2019, 11(6)

PubMed: 31200459 ( click the link to review the publication )

Cells, 2019, 8(2)

PubMed: 30754676 ( click the link to review the publication )

Cell Chem Biol, 2019, 10.1016/j.chembiol.2019.10.013

PubMed: 31735695 ( click the link to review the publication )
Oncoimmunology, 2019, 8(11):e1638207

PubMed: 31646086 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(8):1439-1450

PubMed: 31142662 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0474

PubMed: 31597711 ( click the link to review the publication )

Gastric Cancer, 2019, 10.1007/s10120-019-00977-1

PubMed: 31197522 ( click the link to review the publication )

Hum Mol Genet, 2019, 28(5):842-857

PubMed: 30445628 ( click the link to review the publication )

Eur J Med Chem, 2019, 161:479-492

PubMed: 30388464 ( click the link to review the publication )

J Virol, 2019, 93(14)

PubMed: 31043526 ( click the link to review the publication )

Sci Rep, 2019,

PubMed: 31848373 ( click the link to review the publication )

Sci Rep, 2019, 9(1):6161

PubMed: 30992462 ( click the link to review the publication )

Int J Biol Sci, 2019, 15(9):1942-1954

PubMed: 31523195 ( click the link to review the publication )

Front Pharmacol, 2019, 10:864

PubMed: 31427973 ( click the link to review the publication )

Exp Cell Res, 2019, 111720

PubMed: 31738907 ( click the link to review the publication )

PLoS One, 2019, 14(2):e0212210

PubMed: 30779812 ( click the link to review the publication )

PLoS One, 2019, 14(11):e0221288

PubMed: 31721781 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 519(3):597-604

PubMed: 31540690 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 10.1016/j.bbrc.2019.10.124

PubMed: 31640856 ( click the link to review the publication )

Blood Adv, 2019, 3(7):1185-1196

PubMed: 30967394 ( click the link to review the publication )

Leukemia, 2019, 10.1038/s41375-019-0677-4

PubMed: 31836849 ( click the link to review the publication )

Nat Commun, 2018, 9(1):3982

PubMed: 30266942 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(10):5109-5124

PubMed: 29850896 ( click the link to review the publication )

J Immunother Cancer, 2018, 6(1):59

PubMed: 29925431 ( click the link to review the publication )

Cancer Res, 2018, 78(11):3054-3066

PubMed: 29735549 ( click the link to review the publication )

Cell Rep, 2018, 22(12):3206-3216

PubMed: 29562177 ( click the link to review the publication )

Cancer Lett, 2018, 430:34-46

PubMed: 29753759 ( click the link to review the publication )
J Exp Clin Cancer Res, 2018, 37(1):129

PubMed: 29954437 ( click the link to review the publication )

Cancers (Basel), 2018, 10(5)

PubMed: 29783721 ( click the link to review the publication )

Curr Biol, 2018, 28(23):3824-3832

PubMed: 30449668 ( click the link to review the publication )

Cells, 2018, 7(9)

PubMed: 30200644 ( click the link to review the publication )

Front Oncol, 2018, 8:143

PubMed: 29774202 ( click the link to review the publication )

Sci Rep, 2018, 8(1):948

PubMed: 29343688 ( click the link to review the publication )

Int J Biol Sci, 2018, 14(10):1221-1231

PubMed: 30123071 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):922

PubMed: 30253737 ( click the link to review the publication )

Bioorg Med Chem, 2018, 26(14):4014-4024

PubMed: 29941193 ( click the link to review the publication )

PLoS One, 2018, 13(2):e0193098

PubMed: 29489886 ( click the link to review the publication )

Biomed Res Int, 2018, 2018:5813292

PubMed: 29977914 ( click the link to review the publication )

Oncol Lett, 2018, 16(4):5473-5481

PubMed: 30250620 ( click the link to review the publication )

Blood, 2017, 130(24):2631-2641

PubMed: 29018079 ( click the link to review the publication )

Genes Dev, 2017, 31(3):318-332

PubMed: 28242626 ( click the link to review the publication )

Aging Cell, 2017, 16(3):575-584

PubMed: 28345297 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):77

PubMed: 28356161 ( click the link to review the publication )

J Med Chem, 2017, 60(18):7863-7875

PubMed: 28792760 ( click the link to review the publication )

Br J Cancer, 2017, 117(1):113-123

PubMed: 28535155 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):2022-2034

PubMed: 28619759 ( click the link to review the publication )

J Chromatogr B Analyt Technol Biomed Life Sci, 2017, 1044-1045:70-76

PubMed: 28088043 ( click the link to review the publication )

Sci Rep, 2017, 7:43517

PubMed: 28262781 ( click the link to review the publication )

Oncotarget, 2017, 8(43):73705-73722

PubMed: 29088738 ( click the link to review the publication )

Oncotarget, 2017, 8(7):10966-10979

PubMed: 28030798 ( click the link to review the publication )

Oncotarget, 2017, 8(63):106352-106368

PubMed: 29290954 ( click the link to review the publication )
Oncotarget, 2017, 8(55):94780-94792

PubMed: 29212266 ( click the link to review the publication )

Oncotarget, 2017, 8(27):44295-44311

PubMed: 28574828 ( click the link to review the publication )

Oncotarget, 2017, 8(67):111026-111040

PubMed: 29340034 ( click the link to review the publication )

Oncotarget, 2017, 8(35):59476-59491

PubMed: 28938651 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(17):4440-51

PubMed: 27103402 ( click the link to review the publication )

Stem Cells, 2016, 34(7):1765-75

PubMed: 26946228 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(7):1669-81

PubMed: 27196765 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(6):1332-43

PubMed: 27196784 ( click the link to review the publication )

J Cell Sci, 2016, 129(16):3167-77

PubMed: 27383768 ( click the link to review the publication )

Sci Rep, 2016, 6:33323

PubMed: 27616351 ( click the link to review the publication )

BMC Cancer, 2016, 16:678

PubMed: 27558154 ( click the link to review the publication )

Oncotarget, 2016, 7(27):41320-41335

PubMed: 27191498 ( click the link to review the publication )

Oncotarget, 2016, 7(31):49902-49916

PubMed: 27363019 ( click the link to review the publication )

Oncotarget, 2016, 7(23):34785-99

PubMed: 27166183 ( click the link to review the publication )

Genetics, 2016, 204(2):807-819

PubMed: 27558135 ( click the link to review the publication )

Tumour Biol, 2016, 10.1007/s13277-016-5081-3

PubMed: 27220319 ( click the link to review the publication )

Genes Dev, 2015, 29(5):555-66

PubMed: 25737283 ( click the link to review the publication )

Sci Rep, 2015, 5:16991

PubMed: 26601688 ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(12):1784-93

PubMed: 26529495 ( click the link to review the publication )

Cell Cycle, 2015, 14(7):1070-81

PubMed: 25602147 ( click the link to review the publication )

BMC Cancer, 2015, 15:462

PubMed: 26054341 ( click the link to review the publication )

Pediatr Blood Cancer, 2015, 62(1):52-9

PubMed: 25308916 ( click the link to review the publication )

Radiat Res, 2015, 184(6):660-9

PubMed: 26645158 ( click the link to review the publication )

Oncotarget, 2015, 6(15):13072-87

PubMed: 25965828 ( click the link to review the publication )
Genes Cancer, 2015, 6(5-6):184-213

PubMed: 26124919 ( click the link to review the publication )

Oncotarget, 2015, 6(25):21074-84

PubMed: 26025928 ( click the link to review the publication )

BMC Cancer, 2015, 15:462

PubMed: 26054341 ( click the link to review the publication )

J Thorac Oncol, 2014, 9(7):965-73

PubMed: 24922006 ( click the link to review the publication )

Genes Dev, 2014, 28(14):1578-91

PubMed: 25030697 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(16):4274-88

PubMed: 25125259 ( click the link to review the publication )

J Cell Biol, 2014, 206(7):843-53

PubMed: 25246615 ( click the link to review the publication )

J Hematol Oncol, 2014, 7(1):53

PubMed: 25084614 ( click the link to review the publication )

Cancer Lett, 2014, 356(2 Pt B):656-68

PubMed: 25458954 ( click the link to review the publication )

J Cell Mol Med, 2014, 18(1):143-55

PubMed: 24238094 ( click the link to review the publication )

Pediatr Blood Cancer, 2014, 61(10):1767-73

PubMed: 24962331 ( click the link to review the publication )

Oncotarget, 2014, 5(21):10546-57

PubMed: 25301733 ( click the link to review the publication )

Cell, 2014, 157(3):565-79

PubMed: 24766806 ( click the link to review the publication )

Expert Opin Drug Metab Toxicol, 2013, 9(2):215-24

PubMed: 23320990 ( click the link to review the publication )

PLoS One, 2013, 8(3):e57523

PubMed: 23520471 ( click the link to review the publication )

Obstet Gynecol Int, 2013, 2013:828165

PubMed: 24381593 ( click the link to review the publication )

Mol Cancer Ther, 2012, 11(1):174-82

PubMed: 22084170 ( click the link to review the publication )

Pediatr Surg Int, 2012, 28(6):579-89

PubMed: 22526548 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Wee1 Inhibitors

Biological Activity

Description

Adavosertib (MK-1775, AZD1775) is a potent and selective Wee1 inhibitor with IC50 of 5.2 nM in a cell-free assay; hinders G2 DNA damage checkpoint. Phase 2.

Features

The first reported Wee1 inhibitor.

Targets

Wee1 ^[1]
(Cell-free assay)

5.2 nM

In vitro

MK-1775 inhibits Wee1 kinase in an ATP-competitive manner. Compared to Wee1, MK-1775 displays 2- to 3-fold less potency against Yes with IC50 of 14 nM, 10-fold less potency against seven other kinases with >80% inhibition at 1 μM, and >100-fold selectivity over human Myt 1, another kinase that inhibits cyclin-dependent kinase 1 (CDC2) by phosphorylation at an alternative site (Thr14). By abrogating the DNA damage checkpoint via blockade of Wee1 activity in WiDr cells bearing mutated p53, MK-1775 treatment inhibits the basal phosphorylation of CDC2 at Tyr15 (CDC2Y15) with EC50 of 49 nM, and suppresses gemcitabine-, carboplatin- or cisplatin-induced phosphorylation of CDC2 and cell cycle arrest in a dose-dependent manner, with EC50 of 82 nM and 81 nM, 180 nM and 163 nM, as well as 159 nM and 160 nM, respectively. MK-1775 treatment alone at 30-100 nM has no significant antiproliferative effect in WiDr and H1299 cells, whereas MK-1775 at 300 nM, sufficient to inhibit Wee1 by >80%, displays moderate but significant antiproliferative effects by 34.1% in WiDr cells and 28.4% in H1299 cells. ^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
ASPC-1	NG\MWHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MUTJR\|UxRTF\|LkKgxtEhOS5zIN88US=>	NH;COFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS1PFk2PCd-MkW0OVg6PTR:L3G+
BxPC-3	NGK0cVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MW\JR\|UxRTBwODFCtUAxNjB\|IN88US=>	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR3OEm1OEc,OjV2NUi5OVQ9N2F-
CFPAC-1	M2HpV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NWnGT3VYUUN3ME2zMlMhyrFiMD6yJO69VQ>?	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR3OEm1OEc,OjV2NUi5OVQ9N2F-
HPAC	M3P0cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NULv[VUzUUN3ME2wMlUhyrFiMD6wNUDPxE1?	M4XZOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEW4PVU1Lz5{NUS1PFk2PDxxYU6=
MIAPaCa-2	NX\FTnFtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NGfseIlKSzVyPUCuOUDDuSByLkC1JO69VQ>?	M{DIdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEW4PVU1Lz5{NUS1PFk2PDxxYU6=
PANC-1	NF;pSmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NVryZm1FUUN3ME2xNE43KMLzIEGuNUDPxE1?	Ml7yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2NUi5OVQoRjJ3NEW4PVU1RC:jPh?=
SK-N-BE (2)	NV\n[3R[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Mmi2TWM2OD1{LkVihKnDueLCiUCuN{DPxE1?	NFi4VHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOwPFkyPid-MkWzNFg6OTZ:L3G+
SK-N-BE (2), PAN→MK	MmPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NIXqUmlKSzVyPUK2MlbjiIoEsfMAjVkvPiEQvF2=	NF;E[Jc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOwPFkyPid-MkWzNFg6OTZ:L3G+
SK-N-BE (2), MK→PAN	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2TsWWlEPTB;Mj605qCKyrIkgJmwMlMh\|ryP	Ml7TQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|MEi5NVYoRjJ3M{C4PVE3RC:jPh?=
SK-N-AS	NFvzdVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NYf4ZppnUUN3ME2wMlUx6oDLwsJihKkxNjB{IN88US=>	M3jzTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{C4PVE3Lz5{NUOwPFkyPjxxYU6=
SK-N-DZ	NIPaTVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NFXOfW5KSzVyPUCuN\|bjiIoEsfMAjVAvODFizszN	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTNyOEmxOkc,OjV\|MEi5NVY9N2F-
SK-N-AS	NHz1PJpCeG:ydH;zbZMhSXO\|YYm=	M1X1OVUxOCCwTR?=	M{fwUlQ5KGh?	NFLN[FNqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	MlLDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|MEi5NVYoRjJ3M{C4PVE3RC:jPh?=
SK-N-DZ	NF\ufFVCeG:ydH;zbZMhSXO\|YYm=	MlTFOVAxKG6P	MU[0PEBp	NVTlTGRTcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	M1r2ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{C4PVE3Lz5{NUOwPFkyPjxxYU6=
THP-1	NVvYSGpVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIDrfFQyOjVxMkWwM\|UxOCCwTR?=	MnnlOFghcA>?	MVLpcoNz\WG\|ZYOgZ4VtdCCmZXH0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=>	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB6NE[xOEc,OjVyOES2NVQ9N2F-
MV4-11	MlXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmjzNVI2NzJ3MD:1NFAhdk1?	MU[0PEBp	MX7pcoNz\WG\|ZYOgZ4VtdCCmZXH0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=>	NFXT[W89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC4OFYyPCd-MkWwPFQ3OTR:L3G+
U937	MmWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWCxNlUwOjVyL{WwNEBvVQ>?	MlTjOFghcA>?	MYLpcoNz\WG\|ZYOgZ4VtdCCmZXH0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=>	NHjCZXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC4OFYyPCd-MkWwPFQ3OTR:L3G+
HL-60	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYixNlUwOjVyL{WwNEBvVQ>?	NXHnXXh[PDhiaB?=	NH\Rfm9qdmO{ZXHz[ZMh[2WubDDk[YF1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>?	NYi4TXA{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwPFQ3OTRpPkK1NFg1PjF2PD;hQi=>
OCI-AML3	NULqXVRbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2XzUFEzPS9{NUCvOVAxKG6P	NVftV3JxPDhiaB?=	MmPtbY5kemWjc3XzJINmdGxiZHXheIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI>	NXTwTYp[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwPFQ3OTRpPkK1NFg1PjF2PD;hQi=>
MOLM-13	NIjsPZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUOxNlUwOjVyL{WwNEBvVQ>?	NIPwOJc1QCCq	MYDpcoNz\WG\|ZYOgZ4VtdCCmZXH0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=>	NY\ZUlljRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwPFQ3OTRpPkK1NFg1PjF2PD;hQi=>
CMK	NIryUoNE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MXKxNE0yODByMDDuUS=>	MnzxO\|IhcA>?	NF22WmZz\WS3Y3XzJINmdGxidnnhcIljcXS7IHnuJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgcYFvdmW{	NEK3O4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm2NlM{OSd-MkS5OlI{OzF:L3G+
CMY	NG\wO3FE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MXGxNE0yODByMDDuUS=>	M{ftWFczKGh?	NV3tepR6emWmdXPld{Bk\WyuII\pZYxq[mm2eTDpckBiKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JI1idm6nch?=	M1;EUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OU[yN\|MyLz5{NEm2NlM{OTxxYU6=
Dayo	NHzqfW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Mmj1TWM2OD1zNUCgcm0>	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ4MUmxNEc,OjR4NkG5NVA9N2F-
UW228	M2HCR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NIW3RlZKSzVyPUKzNkBvVQ>?	MmmzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4NkG5NVAoRjJ2Nk[xPVExRC:jPh?=
IST-MES1	MXjD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MXSxOVAwOjVyIH7N	NVP3XJlxPzJiaB?=	MVflcohidmOnczD0bIUh[2m\|cHzheIlvKGO7dH;0c5hq[yCnZn\lZ5QhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI>	M4\wZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{[1O\|gzLz5{NEO2OVc5OjxxYU6=
IST-MES2	NFXUcoRE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	Ml7nNVUxNzJ3MDDuUS=>	NFPZe3E4OiCq	MlvX[Y5p[W6lZYOgeIhmKGOrc4DsZZRqdiCleYTveI95cWNiZX\m[YN1KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN4NUe4Nkc,OjR\|NkW3PFI9N2F-
REN	MWfD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NH:xS\|kyPTBxMkWwJI5O	MlHvO\|IhcA>?	MUPlcohidmOnczD0bIUh[2m\|cHzheIlvKGO7dH;0c5hq[yCnZn\lZ5QhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI>	NEGyflk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO2OVc5Oid-MkSzOlU4QDJ:L3G+
NCI-H2452	MVjD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NGfZToQyPTBxMkWwJI5O	Mn[2O\|IhcA>?	NFLufW5mdmijbnPld{B1cGViY3nzdIxifGmwIHP5eI91d3irYzDl[oZm[3RiaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ?	NHrvOnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO2OVc5Oid-MkSzOlU4QDJ:L3G+
MSTO-211H	MUTD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NIG5XFIyPTBxMkWwJI5O	MVy3NkBp	Mnnk[Y5p[W6lZYOgeIhmKGOrc4DsZZRqdiCleYTveI95cWNiZX\m[YN1KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz	MoXRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR\|NkW3PFIoRjJ2M{[1O\|gzRC:jPh?=
NCI-H2052	MX\D[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NVnBPYMyOTVyL{K1NEBvVQ>?	NYXufpFJPzJiaB?=	M3jhXoVvcGGwY3XzJJRp\SClaYPwcIF1cW5iY4n0c5RwgGmlIHXm[oVkfCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>?	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN4NUe4Nkc,OjR\|NkW3PFI9N2F-
WEE1	M4H0O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NXjC[2dIUUN3ME21MlIhdk1?	M4LyTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|Nkm5OlU2Lz5{M{[5PVY2PTxxYU6=
CDC2	NULLcnJtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M4jn[2lEPTExvK6xNFAxKG6P	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ7OU[1OUc,OjN4OUm2OVU9N2F-
CDK7	NXXMZnVxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NVHpdGVnUUN3MP-8olExODBibl2=	NYfBfYVIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2PVk3PTVpPkKzOlk6PjV3PD;hQi=>
MYT1	NVXrc5p5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NEjYZnNKSzVyPUWzNEBvVQ>?	NVrNWlRqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2PVk3PTVpPkKzOlk6PjV3PD;hQi=>
T98G	MUjBdI9xfG:\|aYOgRZN{[Xl?	MVKxNFAwOjVyIH7N	NXvEVZQ6PiCq	NY[yTWZx\W6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQh[2WubDDrbYxtcW6p	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl7Mke5N{c,OjF7OUK3PVM9N2F-
A549	M4LNR2Fxd3C2b4Ppd{BCe3OjeR?=	NYHCbFVCOjByIH7N	NF;MZnQyKGh?	MkDhdoFlcW:\|ZX7zbZRqgmW\|IF7TR2xEKGOnbHzzJIlvKGFicEWzMYRmeGWwZHXueEBu[W6wZYK=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd7OUCzN{c,OjF5OUmwN\|M9N2F-
H460	NFP1Oo9CeG:ydH;zbZMhSXO\|YYm=	MlzYNlAxKG6P	M1fwflEhcA>?	NFmyWXdz[WSrb4PlcpNqfGm8ZYOgUnNEVENiY3XscJMhcW5iYTDwOVMu\GWyZX7k[Y51KG2jbn7ldi=>	NFjjd3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe5PVA{Oyd-MkG3PVkxOzN:L3G+
H1299	NXHNUIR2SXCxcITvd4l{KEG\|c3H5	NVi5ZlR1OjByIH7N	Ml3vNUBp	NFi5NoRz[WSrb4PlcpNqfGm8ZYOgUnNEVENiY3XscJMhcW5iYTDwOVMu\GWyZX7k[Y51KG2jbn7ldi=>	NFuzWII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe5PVA{Oyd-MkG3PVkxOzN:L3G+
Calu-6	Mn7lRZBweHSxc3nzJGF{e2G7	NY\Sc5FFOjByIH7N	M2PmdlEhcA>?	MlG5doFlcW:\|ZX7zbZRqgmW\|IF7TR2xEKGOnbHzzJIlvKGFicEWzMYRmeGWwZHXueEBu[W6wZYK=	M4PmNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{m5NFM{Lz5{MUe5PVA{OzxxYU6=
WiDr	M1nie2tqdmG\|ZTDBd5NigXN?	NHKxRVYyOC1zMECwNEBvVQ>?	NHP3ZWE5KGh?	M4TjXIlvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kBETEN{IHH0JHR6ejF3IIfpeIgh[W5iRVO1NOKhfmGudXWgc4YhQDVibn3vcE9NKHC{ZYTy[YF1\WRid3n0bEBo\W2laYThZolv\Q>?	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTh6N{W0OUc,OTl6OEe1OFU9N2F-
Function assay	NHi4c5VGgHCrMkmzSi=>			M{PzOWJqdmSrbnegZYZncW6rdImgeI8hemWlb33ibY5idnRiaIXtZY4h\nWubD3s[Y5ofGhiTj30[ZJucW6jbDDIbZM5NXSjZ3fl[EBY\WVzIDixJJRwKDZ2NjDy[ZNq\HWnczmg[ZhxemW\|c3XkJIlvKGi3bXHuJGV5eGl{OUPGJINmdGy\|IHHzd4V{e2WmIHHzJIRme3OxY3nheIlwdiClb37zeIFvfCCkeTDxeYFvfGm2YYTpeoUhemWjbD30bY1mKFCFUjDt[ZRpd2RuIFvkJF0hOC5yMEOyJO69VS5?	MmnhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh5OUK3OlAoRjJ6N{myO\|YxRC:jPh?=
Function assay	NITtVJhGgHCrMkmzSi=>			M1eyeGJqdmSrbnegZYZncW6rdImgeI8hemWlb33ibY5idnRiaIXtZY4h\nWubD3s[Y5ofGhiTj30[ZJucW6jbDDIbZM5NXSjZ3fl[EBY\WV{IDixJJRwKDV4NzDy[ZNq\HWnczmg[ZhxemW\|c3XkJIlvKGi3bXHuJGV5eGl{OUPGJINmdGy\|IHHzd4V{e2WmIHHzJIRme3OxY3nheIlwdiClb37zeIFvfCCkeTDxeYFvfGm2YYTpeoUhemWjbD30bY1mKFCFUjDt[ZRpd2RuIFvkJF0hOC5yMEO5JO69VS5?	NWjzVmhORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3PVI4PjBpPkK4O\|kzPzZyPD;hQi=>
Antiproliferative assay	MUfNSGEuVUJvMkOx		NFHZOVY4OiCqcoO=	NEfNcYJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNibXXhd5Vz\WRiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2EbIXlJIF{e2G7LDDJR\|UxKD1iMD6yOkDPxE1w	NFLIeJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEe5Nlc3OCd-Mki3PVI4PjB:L3G+
Antiproliferative assay	MV;ISWszQTOW		NELJTmU4OiCqcoO=	MVHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IFjFT\|I6O1RiY3XscJMhdWWjc4Xy[YQh[W[2ZYKgO\|IhcHK\|IHL5JGNmdGyWaYTldk1DdHWnIHHzd4F6NCCLQ{WwJF0hOC5{OTFOwG0v	MlLmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh5OUK3OlAoRjJ6N{myO\|YxRC:jPh?=
Antiproliferative assay	NXfqenFPVU1zUx?=		M3;ZZlczKGi{cx?=	M3v2SmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTV2xV{Bk\WyuczDt[YF{fXKnZDDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVLseYUh[XO\|YYmsJGlEPTBiPTCwMlMyKM7:TT6=	MlzvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh5OUK3OlAoRjJ6N{myO\|YxRC:jPh?=
Function assay	MXXISWszQTN?		NVTx[oJoOSCqch?=	MYLJcohq[mm2aX;uJI9nKGi3bXHuJIZ2dGxibHXu[5RpKFCNTWnUNUBmgHC{ZYPz[YQhcW5iSFXLNlk{KGOnbHzzJJV{cW6pIFXGV{ApOjR5IITvJFI2QSC{ZYPp[JVmeyliYYOgd5Vje3S{YYTlJIFnfGW{IEGgbJIh[nliZnz1c5Jme2OnbnPlJJBwdGG{aYrheIlwdiCrbX31co9ie2G7LDDLbUA:KDBwNEeg{txONg>?	NH[4fVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUm0NVE6Oyd-Mkm5OFEyQTN:L3G+
Function assay	NGDCW4ZJTUt{OUO=		MXOxJIhz	M1XOZmlvcGmkaYTpc44hd2ZiaIXtZY4h\nWubDDs[Y5ofGhiUFvNXXQyKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMhfXOrbnegSWZUKCh{NEegeI8hOjV7IILld4llfWW\|KTDhd{B{fWK\|dILheIUh[W[2ZYKgNUBpeiCkeTDmcJVwemW\|Y3XuZ4UheG:uYYLpfoF1cW:wIHntcZVvd2G\|YYmsJGlEPTBiPTC0Mlk1KM7:TT6=	M2HORVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7OUSxNVk{Lz5{OUm0NVE6OzxxYU6=
Function assay	MmPJUWRCNU2ELUKzNS=>	NXrBc5c3OC5zIITvJFExKHWP	NIDzUWo3KGi{cx?=	NUWyeXFbUW6qaXLpeIlwdiCxZjDX[YUyKGmwIHj1cYFvKE2GQT3NRk0zOzFiY3XscJMh[XO\|ZYPz[YQh[XNiZHXjdoVie2ViaX6gR2RMOSCyaH;zdIhwenmuYYTpc44h[XRiVInyJFE2KGG2IECuNUB1dyBzMDD1UUBi\nSncjC2JIhzeyCkeTDX[ZN1\XKwIHLsc5QhdWW2aH;k	M4XkSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{myO\|YxLz5{OEe5Nlc3ODxxYU6=
Function assay	NY\P[2QxUEWNMkmzWC=>	MlXZNE4yKHSxIEGwJJVO	NWPqb5REPiCqcoO=	MUXJcohq[mm2aX;uJI9nKFenZUGgbY4hUEWNMkmzWEBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCFRFuxJJBpd3OyaH;yfYxifGmxbjDheEBVgXJzNTDheEAxNjFidH:gNVAhfU1iYX\0[ZIhPiCqcoOgZpkhX2W\|dHXyckBjdG:2IH3leIhw\A>?	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDd7Mke2NEc,Ojh5OUK3OlA9N2F-
Function assay	NWLKRmhTUEWNMkmzWC=>	NXzkcJBDOC5zIITvJFExKHWP	MWq2JIhzew>?	NGLQ[mhKdmirYnn0bY9vKG:oIGDMT\|EhcW5iSFXLNlk{XCClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDUR3RRKHCqb4PwbI9zgWyjdHnvckBifCByLkGgeI8hOTBidV2gZYZ1\XJiNjDodpMh[nliV3XzeIVzdiCkbH;0JI1mfGixZB?=	M4nyPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{myO\|YxLz5{OEe5Nlc3ODxxYU6=
Function assay	MoXDUWRCNU2ELUKz	M1zpb\|AvOSC2bzCxNEB2VQ>?	NYm1c45xPiCqcoO=	MUPJcohq[mm2aX;uJI9nKFCOS{GgbY4hcHWvYX6gUWRCNU2ELUKzJINmdGy\|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKFSFVGCgdIhwe3Cqb4L5cIF1cW:wIHH0JFAvOSC2bzCxNEB2VSCjZoTldkA3KGi{czDifUBY\XO2ZYLuJIJtd3RibXX0bI9l	M2D5eFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{myO\|YxLz5{OEe5Nlc3ODxxYU6=
qHTS assay	MXHUR\|Mz			MojxdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFSFM{KgZ4VtdHN?	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
qHTS assay	NWfROZY5XS1{IF;T			M2P3XpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCXLUKgU3Mh[2WubIO=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
qHTS assay	NUXqbXlWSTZ5Mx?=			Mo[4dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEF4N{OgZ4VtdHN?	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
qHTS assay	Ml\JSGFQYQ>?			MYnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhTEGRWTDj[Yxtew>?	M1vsUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
qHTS assay	MYXTZY9{NTJ?			M1LJepFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVYX;zMVIh[2WubIO=	M{\lbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
qHTS assay	NFX6ZWpDXC1\|Nx?=			NXfHUGNYeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFLUMVM4KGOnbHzz	NIi3[pA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
qHTS assay	M{DJR3JF			NXTEZ\|NreUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLEJINmdGy\|	MmLIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay	NY\ub4NXW0tvTj3TTC=>			M37MU5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMXNJKGOnbHzz	M1i5eFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
qHTS assay	M2G2VWJVNTF{			NWHBflZNeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFLUMVEzKGOnbHzz	NYLPZVMyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay	MkmxUmIyPjR\|			M{jTfZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQkG2OFMh[2WubIO=	Mlv2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay	NX7xSI86V0iVLUWw			MWDxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy\|	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
qHTS assay	Ml6wRnQuOTJ?			MorKdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgRnQuOTJiY3XscJM>	MoPOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay	NUnnRVM2TEGRWR?=			NF7Db4xyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBFSU:\IHPlcIx{	NFjlcIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
qHTS assay	M2XydnNMNU5vU1i=			NI[x[FJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBUUy2QLWPIJINmdGy\|	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
qHTS assay	MYPSbFQy			M{DpU5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaESxJINmdGy\|	NHr1UYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
qHTS assay	NWPUZXdxSTZ5Mx?=			M4P6XJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGE3PzNiY3XscJMq	NYfE[HFURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay	NXPEUJc3VUdiNkOgLFYuXEdiUjm=			NUDLdol5eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhVUdiNkOgLFYuXEdiUjmgZ4VtdHN?	NUf2U2pCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay	NEXBWZFWNTJiT2O=			NI\O[YdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBWNTJiT2OgZ4VtdHN?	M2HEeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
qHTS assay	NE\B[olQUFNvNUC=			NXHIcJpxeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy\|	Mnv2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay	MUTSbFQy			MXjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDSbFQyKGOnbHzz	Ml\tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay	NGDrUYlTTA>?			M1rVfJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJFKGOnbHzz	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
qHTS assay	MUXTTk1ISk1{			NH;JRYZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=>	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
qHTS assay	M2TJW3NMNU5vTVO=			MkGydWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO=	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
qHTS assay	MWPORk1GSmNz			NGTmcY5yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKtSWJkOSClZXzsdy=>	NFf6Tow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
qHTS assay	MoDIUGFPNTV?			MljxdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEyDTj21JINmdGy\|	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
qHTS assay	MVLSbFE5			Ml\WdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqMUigZ4VtdHN?	NITteZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
qHTS assay	NV7zNYN1W0pvR1LNNi=>			NFz6cZZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBUUi2JQl2yJINmdGy\|	Mn\iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay	MVHTZY9{NTJ?			NW\mTlVVeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW2Gxcz2yJINmdGy\|	NG\m[Yc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-Cdk1(Y15) / Cdk1; PubMed: 25609063 Clin Cancer Res The impact of a 24 hour pre-treatment of MK-1775 on p-Cdk1 was assessed by western blotting. Because of low basal phosphorylation, GBM22 was irradiated (RT) with 10 Gy. p-KAP1(S824) / p-Chk2(T68) / p-Chk1(S345); PubMed: 25609063 Clin Cancer Res Western blot evaluation of GBM6 and GBM22 short-term explant cultures 24 hours after treatment with either MK-1775 or TMZ or the combination. PARP / CF-PARP / pH3(S10) / p-CDC25c(S216) / p-CDK2(Y15); PubMed: 25458954 Cancer Lett Pancreatic cancer cells were treated with vehicle control or 500 nM MK-1775 for 48 h. Whole cell lysates were subjected to Western blotting and probed with anti-PARP, -p-H3, -γH2AX, -p-CHK1, -CHK1, -p-CDC25C, -p-CDK1, - CDK1, -p-CDK2, -CDK2, or -β-actin antibody. WEE1; PubMed: 27616351 Sci Rep MIA PaCa2, PANC-1, Hs 766T, Capan-1 and PL11 cells were treated with MK-1775 (400 nM/L) and/or MMC (150 nM/L) for 24 hours. Whole cell lysates were prepared using RIPA and western blot was performed to assess the protein expression of WEE1 (90 kDa), pCDK1(y15) (34 kDa), CDK1 (34 kDa) and GAPDH (36 kDa) as loading control.	25609063 25458954 27616351
Immunofluorescence	tubulin / p-HH3(S10); PubMed: 30755439 Clin Cancer Res FaDu and UNC7 cells were treated with adavosertib (500 nM), alisertib (250 nM), or adavosertib + alisertib for 24 hours and followed by immunofluorescent staining with anti-tubulin (Green) and anti-pHH3 (S10; Red). Nucleus was stained with DAPI. (A) Representative images of mitotic cells were captured by confocal microscopy. Scale bar: 10 µm. γH2AX; PubMed: 25609063 Clin Cancer Res A) γH2AX foci formation in GBM6 and GBM22 were assessed 24 h after a single treatment of 300 nM MK-1775. Cleaved caspase-3 / pH3; PubMed: 27616351 Sci Rep MIA PaCa2 cells were treated and dual stained with pH3 to observe mitotic entry; and cleaved caspase 3 (CL-CSP3) to observe caspase 3 activity.	30755439 25609063 27616351
Growth inhibition assay	Cell viability; PubMed: 25458954 Cancer Lett Pancreatic cancer cell lines were cultured in 96-well plates at 37℃ for 48 h in complete medium with variable concentrations of MK-1775 and viable cell numbers were determined using MTT reagent and a microplate reader. The data are presented as means ± standard errors from at least 3 independent experiments. IC50; PubMed: 25084614 J Hematol Oncol AML cell lines were cultured for 72 h in complete medium with variable concentrations of MK-1775 (MK) and viable cell numbers were determined using MTT assays. IC50 values were calculated as drug concentration necessary to inhibit 50% growth compared to untreated control cells.	25458954 25084614

In vivo

MK-1775 treatment alone at ~20 mg/kg displays minimal antitumor effects against WiDr xenografts in rats with T/C of 69% at day 3. Antitumor efficacy by MK-1775 alone in the nude rat HeLa-luc and TOV21G-shp53 xenograft models is also moderate. ^[1]

Protocol

Kinase Assay: ^[1]	- Collapse In vitro kinase assays: Recombinant human Wee1 is used. Kinase reaction is conducted with 10 μM ATP, 1.0 μCi of [γ-³³P]ATP, and 2.5 μg of poly(Lys, Tyr) as a substrate in the presence of increasing concentrations of MK-1775 at 30°C for 30 minutes. Radioactivity incorporated into the substrate is trapped on MultiScreen-PH plates and is counted on a liquid scintillation counter.
Cell Research: ^[1]	- Collapse Cell lines: WiDr, NCI-H1299, TOV21G, and HeLa Concentrations: Dissolved in DMSO, final concentrations ~10 μM Incubation Time: 24 hours Method: Cells are treated with or without gemcitabine for 24 hours, then with MK-1775 for an additional 24 hours. Cell viability is determined with a WST-8 kit using SpectraMax. Cellular caspase-3/7 activities are determined with a Caspase-3/7 Glo kit. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Immunodeficient nude rats (F344/NJcl-rnu) bearing WiDr, HeLa-luc, or TOV21G-shp53 tumors Dosages: ~20 mg/kg/day Administration: Orally (Only for Reference)

References

[1] Hirai H, et al. Mol Cancer Ther, 2009, 8(11), 2992-3000.

Solubility (25°C)

In vitro	DMSO	80 mg/mL (159.8 mM)
	Ethanol	10 mg/mL (19.97 mM)
	Water	0.0001 mg/mL (0.0 mM)
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Adavosertib (MK-1775) SDF

Molecular Weight	500.6
Formula	C₂₇H₃₂N₈O₂
CAS No.	955365-80-7
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	AZD1775
Smiles	CC(C)(C1=NC(=CC=C1)N2C3=NC(=NC=C3C(=O)N2CC=C)NC4=CC=C(C=C4)N5CCN(CC5)C)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03668340	Recruiting	Drug: AZD1775	Uterine Cancer	Dana-Farber Cancer Institute\|AstraZeneca	October 22 2018	Phase 2
NCT03028766	Active not recruiting	Drug: AZD1775\|Drug: Cisplatin\|Radiation: Radiotherapy	Hypopharynx Squamous Cell Carcinoma\|Oral Cavity Squamous Cell Carcinoma\|Larynx Cancer	University of Birmingham\|AstraZeneca\|Cancer Research UK	June 22 2017	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How to prepare MK1775 methylcellulose solution? and how to prepare methylcellulose itself? Once make the MK1775 methylcellulose solution, how should i keep it?
Answer:
MK1775 in 0.5% methylcellulose is a suspension or emulsion, and it is ok to treat mice orally. It is recommended to dissolve methylcellulose in saline. It will take some time to dissolve methylcellulose, and you can vortex it for a while. The MK1775 methylcellulose solution can be stored at 4°C for a week.

Wee1 Signaling Pathway Map

Related Wee1 Products

Ro-3306 ^New

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases. RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis.
CCG-1423 ^New

CCG-1423 is a specific RhoA pathway inhibitor, which inhibits SRF-mediated transcription.
ML141 ^New

ML141 (CID-2950007) is demonstrated to be a potent, selective and reversible non-competitive inhibitor of Cdc42 GTPase suitable for in vitro assays, with IC50 of 200 nM and selectivity against other members of the Rho family of GTPases (Rac1, Rab2, Rab7). ML141 is associated with an increase in p38 activation and may induce p38-dependent apoptosis/senescence. ML141 also protects neuroblastoma cells from metformin-induced apoptosis.
Y-27632 2HCl

Y-27632 2HCl is a selective ROCK1 (p160ROCK) inhibitor with K_i of 140 nM in a cell-free assay, exhibits >200-fold selectivity over other kinases, including PKC, cAMP-dependent protein kinase, MLCK and PAK.
Palbociclib (PD-0332991) HCl

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Features:Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).
Alisertib (MLN8237)

Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Alisertib induces cell cycle arrest, apoptosis and autophagy. Phase 3.

Features:First orally available inhibitor of Aurora A.
Palbociclib (PD0332991) Isethionate

Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Features:The 1st specific inhibitor for CDK4/6 to show promise in multiple cancers.
Dinaciclib (SCH727965)

Dinaciclib (SCH727965, PS-095760) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM in cell-free assays, respectively. It also blocks thymidine (dThd) DNA incorporation. Dinaciclib induces apoptosis through the activation of caspases 8 and 9. Phase 3.
BI 2536

BI-2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM in a cell-free assay. BI-2536 inhibits Bromodomain 4 (BRD4) with Kd of 37 nM and potently suppresses c-Myc expression. BI-2536 induces apoptosis and attenuates autophagy. Phase 2.

Features:The first potent and selective Plk1 inhibitor that induces all hallmarks of Plk1 inhibition.
Barasertib (AZD1152-HQPA)

Barasertib (AZD1152-HQPA, AZD2811, INH-34) is a highly selective Aurora B inhibitor with IC50 of 0.37 nM in a cell-free assay, ~3700 fold more selective for Aurora B over Aurora A. Phase 1.

Choose Your Country or Region

By Signaling Pathways

By product type

Adavosertib (MK-1775)